NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE
Clinical Trials
63
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
- Conditions
- GlioblastomaGlioblastoma Multiforme (GBM)
- First Posted Date
- 2025-07-07
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07052877
- Locations
- 🇦🇺
Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
Pelvis Adaptive Radiotherapy (ART)
- Conditions
- Pelvis Neoplasms
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT06650033
- Locations
- 🇦🇺
Northern Sydney Local Health District, St Leonards, New South Wales, Australia
Locally Optimised Contouring With AI Technology for Radiotherapy
- Conditions
- Radiation TherapyArtificial IntelligenceDeep LearningContouringSegmentation
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 444
- Registration Number
- NCT06546592
- Locations
- 🇦🇺
Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺Western Cancer Centre Dubbo, Dubbo, New South Wales, Australia
🇦🇺Central West Cancer Centre, Orange, New South Wales, Australia
Prostate Adaptive Radiation Therapy
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT06547398
- Locations
- 🇦🇺
Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia
3D Printed Custom Applicators for HDR BT (DISCO)
- Conditions
- Vulva CancerGynecologic CancerVaginal CancerEndometrial Cancer
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Royal North Shore Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06432478
- Locations
- 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Aethlon Medical Advances Hemopurifier Cancer Trial with First Three Patients Treated and Indian Regulatory Approval
Aethlon Medical successfully treated the first three patients in its Hemopurifier cancer trial at Australian hospitals, with all participants completing 4-hour treatments without device deficiencies or immediate complications.
Aethlon Medical Advances Hemopurifier Cancer Trial with Second Patient Treatment in Australia
Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies.
Strand Therapeutics Reports Promising Phase 1 Data for Novel mRNA Cancer Therapy STX-001
Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors.
Regorafenib Shows Survival Benefit in Late-Stage Gastric Cancer INTEGRATE IIa Trial
• Phase 3 INTEGRATE IIa trial demonstrates regorafenib extends median overall survival to 4.5 months versus 4.0 months with placebo in refractory advanced gastric/GEJ cancer patients. • Treatment with regorafenib significantly delayed disease progression and quality-of-life deterioration, with a progression-free survival of 1.8 months compared to 1.6 months for placebo. • The study validates regorafenib's potential as a treatment platform, supporting its investigation in combination therapies including ongoing trials with nivolumab and chemotherapy.